Management Team
Tim Wilson
Chief Executive Officer
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
Kevin FitzGerald
Chief Scientific Officer
Kevin began his career in the biotechnology industry at Cambridge Antibody Technology (now part of Medimmune, an AstraZeneca company) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.
Ian Ardill
Chief Financial Officer
Ian is an experienced finance executive with 20 years’ experience in pharmaceutical and medical technology companies. He was CFO of Diurnal Group, where he managed the company’s IPO and admission to the AIM Market; Lombard Medical, where he was responsible for the company’s final AIM fundraising followed by its AIM delisting and IPO on NASDAQ; and Biocompatibles International, where he led the group financially to profitability and subsequent sale to BTG. Ian’s experience includes IPOs, fundraising, acquisitions and disposals in private and public Life Sciences companies along with supporting early stage companies with their financial and accounting needs. He is a qualified Chartered Accountant.
Leanne Partington
Director of Product Development
Leanne has over 20 years’ experience developing therapeutics from bench to clinic. She has worked as a scientist to develop vaccines at the Defence Science and Technology Laboratory (Dstl), GlaxoSmithKline on the development of small molecules and monoclonal antibodies and then the Cell and Gene Therapy Catapult with focus on the translation of cell and gene therapies. Leanne then moved into project management at University College London (UCL), working with academics and clinicians at UCL to secure translational research grants for the development of biologics, cell therapy and medical device modalities and then managing these grants with particular focus on funder liaison and sub-contractor management. She gained her EngD in Biochemical Engineering from University College London and is an APM PMQ qualified project manager